BC Extra | Jan 11, 2020
Company News

Led by Blatt, Aligos reunites Alios team to develop functional cure for HBV

Led by a team of veterans from Alios BioPharma and Janssen, Aligos Therapeutics raised $125 million in a series B round to bring three of its HBV therapies to the clinic this year. Aligos thinks...
BC Extra | Nov 1, 2019
Clinical News

Hepatitis D draft guidance outlines surrogate endpoints

Two companies have chronic hepatitis D virus therapies in Phase III trials with designs that could support accelerated approval, based on an FDA draft guidance released Friday. There are no approved drugs for HDV, though...
BC Extra | Oct 31, 2019
Company News

Dicerna’s latest deal lands $200M, Roche as partner in HBV

A year after completing a pair of deals in the span of a week, Dicerna has partnered a Phase I HBV asset with Roche in an RNAi deal that brings in $200 million up front....
BC Extra | Oct 4, 2019
Clinical News

Arbutus scuttles lead HBV capsid inhibitor program

Arbutus scrapped plans to start a combination trial next year due to the emergence of a safety signal in two healthy volunteers in a Phase I study of AB-506, an oral capsid inhibitor expected to...
BC Extra | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

Although more than half of the $630.7 million in equity funding that Vir Biotechnology has raised remains unspent, the immunology and infectious disease company -- led by former Biogen and Exelixis CEO George Scangos --...
BC Innovations | Jul 11, 2019
Distillery Therapeutics

Adoptive transfer with T cells expressing anti-HBV TCRs for HBV

DISEASE CATEGORY: Infectious disease INDICATION: Hepatitis B virus (HBV) T cells engineered to express HBV-specific TCRs could help treat HBV infection. Incubation of HBV-infected human liver cells with HBV-targeted T cells reduced hepatocyte levels of...
BC Week In Review | Nov 30, 2018
Company News

Ascletis adds HBV therapy to portfolio through Roche partnership

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Nov. 20 with exclusive rights to marketed HBV drug Pegasys...
BC Extra | Nov 20, 2018
Company News

Ascletis adds marketed HBV drug from Roche to Chinese portfolio

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Tuesday with exclusive rights to marketed HBV drug Pegasys peginterferon...
BC Extra | Nov 1, 2018
Politics & Policy

FDA guides development of finite therapies to cure HBV

FDA released draft guidance Thursday to encourage development of finite, curative HBV treatments that have a low risk of virologic relapse and minimal risk of liver disease progression after treatment. FDA recommended developers use a...
BC Week In Review | Oct 12, 2018
Company News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Oct. 9 after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market...
Items per page:
1 - 10 of 268